Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Polypharmacy in multiple sclerosis

L W Myers1, J T Phillips

  • 1Department of Neurology, UCLA School of Medicine, USA. 1LU0LWM@MVS.OAC.UCLA.edu

Epilepsy Research. Supplement
|January 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Time course of clinical and neuroradiological effects of delayed-release dimethyl fumarate in multiple sclerosis.

European journal of neurology·2015
Same author

The Biochemical characterization of syrian hamster cell-surface alloantigen : I. Analysis of allogeneic differences between recently wild and highly inbred hamsters.

Immunogenetics·2011
Same author

Assessment of hepatic inflammation after spinal cord injury using intravital microscopy.

Injury·2011
Same author

Gender effects on intramuscular interferon beta-1a in relapsing-remitting multiple sclerosis: analysis of 1406 patients.

Multiple sclerosis (Houndmills, Basingstoke, England)·2010
Same author

Why Report Communicable Diseases?

Journal of the National Medical Association·2010
Same author

Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy.

Neurology·2008
Same journal

Proceedings of the 3rd WONOEP Symposium. Tromso, Norway, June 1993.

Epilepsy research. Supplement·1996
Same journal

The relationship between seizures and damage in the maturing brain.

Epilepsy research. Supplement·1996
Same journal

Seizure-induced molecular changes, sprouting and synaptogenesis of hippocampal mossy fibers.

Epilepsy research. Supplement·1996
Same journal

Astrocytes may contribute to the latent period in progressive neuron loss, axon sprouting, and chronic seizures in rat kainate hippocampal epilepsy.

Epilepsy research. Supplement·1996
Same journal

Bilateral hippocampal sclerosis and secondary epileptogenesis.

Epilepsy research. Supplement·1996
Same journal

Structural impairment of hippocampal neurons following a single epileptic afterdischarge.

Epilepsy research. Supplement·1996
See all related articles

This study explores how treating multiple sclerosis (MS) with multiple medications (polypharmacy) offers insights for managing epilepsy. Principles from MS care may guide more effective epilepsy treatment strategies.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Clinical Medicine

Background:

  • Multiple Sclerosis (MS) management frequently involves polypharmacy, a trend expected to grow.
  • Epilepsy shares certain pathological similarities with MS, suggesting potential therapeutic overlaps.

Purpose of the Study:

  • To explore therapeutic strategies for MS, particularly polypharmacy, applicable to epilepsy treatment.
  • To identify analogies between MS and epilepsy to inform treatment approaches.
  • To suggest principles for rational polypharmacy in neurological disorders.

Main Methods:

  • Review of current literature on MS etiology, pathogenesis, and therapeutic targets.
  • Analysis of polypharmacy approaches used in multiple sclerosis care.
  • Comparison of therapeutic principles between MS and epilepsy.

Related Experiment Videos

Main Results:

  • Identified potential therapeutic targets in MS based on its pathogenesis.
  • Described the polypharmacy strategies currently used for MS patients.
  • Highlighted analogies between MS and epilepsy relevant to treatment.

Conclusions:

  • Therapeutic principles from MS polypharmacy may be transferable to epilepsy management.
  • Rational polypharmacy offers a framework for treating complex neurological conditions.
  • Overcoming obstacles to expanding rational polypharmacy is crucial for improved patient outcomes.